NCT06718686RecruitingPhase 1/2
Rifaximin SSD in Dementia Trial
Rifaximin in Dementia Trial (RIDE): Gut-Brain Modulation With Rifaximin SSD in Dementia
Source: ClinicalTrials.gov · Last updated 3 Apr 2026
Brief summary (registry, in English)
Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 2 Dec 2024
- Start date
- 30 Dec 2024
- Primary completion date
- 30 Oct 2027
- Lead sponsor
- Jasmohan Bajaj
- Diseases
- Alzheimer disease
- NCT number
- NCT06718686
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 20
- From 30 Dec 2024 to the primary completion date, 30 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Clinically significant agitation or aggression (requiring treatment with antipsychotic medication)
- Antibiotic use in the prior 6 months
- Taking medications that interact with Rifaximin. P-glycoprotein (P-gp) inhibitor treatment is permitted as long as the use of P-gp inhibitors is discussed with the investigator.
- Participation in another investigational drug trial in the last 30 days
Other illness
- Dementia not due to AD or VaD
- Unstable, severe, or poorly controlled medical conditions evident from physical examination or clinical history
- Visual and/or hearing disorder that prevents completion of neuropsychologic evaluations.
- Hypersensitivity to rifaximin, components of rifaximin,
- History of alcohol and/or drug abuse
Other
- Delusions and/or hallucinations
- Severe psychopathology including major depression
- Diarrhea
- and any rifamycin antimicrobial agent
Who the study is looking for
- Probable Alzheimer's Disease (AD) or Vascular Dementia (VaD) mild or moderate based on Clinical Dementia Rating Scale.
- Males and Females Age ≥ 65 years
- Community living with availability of caregiver to accompany participant to study visits and to participate in the study.
- Able to consent or legal guardian who can consent (with participant assent).
- Legally authorized representative (LAR) and caregiver for the study is the same individual.
- Fluency (both participant and caregiver) in written and spoken English to participate in study visits.
Age in the registry: 65 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Richmond VA Medical Center Coordinator of this site? Confirm its status | Richmond | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.